Time to Viral Suppression is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin

被引：0
|
作者：
Sulkowski, Mark S. [1 ]
Fried, Michael W. [11 ]
Ozaras, Resat [3 ]
Isakov, Vasily [4 ]
Wyles, David L. [5 ]
Ferenci, Peter [6 ]
Feld, Jordan J. [7 ]
Calinas, Filipe [8 ]
Gschwantler, Michael [9 ]
King, Martin [10 ]
Baykal, Tolga [10 ]
Gane, Edward J. [2 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Auckland City Hosp, Liver Unit, Auckland, New Zealand
[3] Istanbul Univ, Istanbul, Turkey
[4] Russian Acad Med Sci, Inst Nutr, Moscow 109801, Russia
[5] Univ Calif San Diego, La Jolla, CA 92093 USA
[6] Univ Klin Fuer Innere Med III, Vienna, Austria
[7] Univ Toronto, Toronto Ctr Liver Dis, Toronto, ON, Canada
[8] EPE Hosp St Antonio Capuchos, Ctr Hosp Lisboa Cent, Lisbon, Portugal
[9] Wilhelminenspital Stadt Wien, Vienna, Austria
[10] AbbVie, N Chicago, IL USA
[11] Univ N Carolina, Liver Program, Chapel Hill, NC USA
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1950
引用
收藏
页码：1144A / 1145A
页数：2
相关论文
共 50 条
  • [21] Adverse event profile of the interferon-free all-oral abt-450/r/ombitasvir, dasabuvir, and ribavirin regimen in HCV patients
    Jensen, D. M.
    Baykal, T.
    Lawitz, E.
    Feld, J. J.
    Angarano, G.
    Jayakumar, S.
    Welzel, T. M.
    Coakley, E.
    Xiong, J. J.
    Da Silva-Tillmann, B.
    Larsen, L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 155 - 155
  • [22] ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials
    Nelson, David R.
    Reddy, K. Rajender
    Di Bisceglie, Adrian M.
    Ferenci, Peter
    Crawford, Darrell H.
    Stauber, Rudolf E.
    Yakovlev, Alexey A.
    de Ledinghen, Victor
    Hinrichsen, Holger
    Bernstein, David Eric
    de Knegt, Robert J.
    Hassanein, Tarek
    Norris, Suzanne
    Xiong, Junyuan J.
    McGovern, Barbara H.
    Agarwal, Kosh
    HEPATOLOGY, 2014, 60 : 1159A - 1160A
  • [23] A Meta-Analysis of the Association Between Pre-Treatment Variables and SVR Amongst Genotype 1 Patients Treated with ABT-450/r-Ombitasvir and Dasabuvir (VIEKIRA PAK™) plus Ribavirin for 12 Weeks
    Botwin, Gregory J.
    Morgan, Timothy R.
    HEPATOLOGY, 2015, 62 : 766A - 766A
  • [24] PHASE 3B STUDIES TO ASSESS LONG-TERM CLINICAL OUTCOMES IN HCV GT1-INFECTED PATIENTS TREATED WITH OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN
    Dumas, E. O.
    Enejosa, J.
    Ball, G.
    Hu, Y. B.
    Co, M.
    Pothacamury, R. Kumar
    Liu, Y.
    Shulman, N.
    Podsadecki, T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S855 - S855
  • [25] ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials
    Puoti, Massimo
    Cooper, Curtis
    Sulkowski, Mark S.
    Foster, Graham R.
    Berg, Thomas
    Villa, Erica
    Rodriguez-Perez, Federico
    Rustgi, Vinod
    Wyles, David L.
    King, Martin
    McGovern, Barbara H.
    Wedemeyer, Heiner
    HEPATOLOGY, 2014, 60 : 1135A - 1136A
  • [26] ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS
    Lawitz, E.
    Poordad, F.
    DeJesus, E.
    Kowdley, K.
    Gaultier, I.
    Cohen, D.
    Xie, W.
    Larsen, L.
    Pilot-Matias, T.
    Menon, R. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S470 - S470
  • [27] ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
    Andreone, Pietro
    Colombo, Massimo G.
    Enejosa, Jeffrey V.
    Koksal, Iftihar
    Ferenci, Peter
    Maieron, Andreas
    Muellhaupt, Beat
    Horsmans, Yves
    Weiland, Ola
    Reesink, Henk W.
    Rodrigues, Lino, Jr.
    Hu, Yiran B.
    Podsadecki, Thomas
    Bernstein, Barry
    GASTROENTEROLOGY, 2014, 147 (02) : 359 - +
  • [28] PEARL-III: 12 WEEKS OF ABT-450/R/267+ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN
    Ferenci, P.
    Nyberg, A.
    Enayati, P.
    Bernstein, D.
    Baruch, Y.
    Caruntu, F. A.
    Chulanov, V.
    Janczewska, E.
    Younes, Z.
    Marinho, R. T.
    Rizzardini, G.
    Gervain, J.
    Planas, R.
    Moreno, C.
    Xie, W.
    Cohen, D.
    King, M.
    Podsadecki, T.
    Reddy, K. R.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S527 - S527
  • [29] Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 with SVR24 After Treatment with ABT-450/r, ABT-267, ABT-333+Ribavirin in Patients with Chronic HCV Genotype 1 Infection in the AVIATOR Study
    Poordad, Fred
    Agarwal, Kosh
    Younes, Ziad
    Cohen, Daniel E.
    Xie, Wangang
    Podsadecki, Thomas
    HEPATOLOGY, 2013, 58 : 735A - 736A
  • [30] High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir plus Dasabuvir Plus Ribavirin
    Mantry, Parvez S.
    Kwo, Paul Y.
    Coakley, Eoin
    Te, Helen S.
    Vargas, Hugo E.
    Brown, Robert S.
    Gordon, Fredric D.
    Levitsky, Josh
    Terrault, Norah
    Burton, James R.
    Xie, Wangang
    Setze, Carolyn
    Badri, Prajakta
    Vilchez, Regis A.
    Forns, Xavier
    HEPATOLOGY, 2014, 60 : 298A - 299A
12345